Application of oxytocin in ultrasound-guided percutaneous microwave ablation for treatment of hypervascular uterine fibroids: a preliminary report.

Fu Y, Feng Q, Zhang S, Li Y

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group1 Jan 2019Cited by 13 (Europe PMC)

PMID31431080DOI10.1080/02656736.2019.1639832PepBankPUB-31431080

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

Objective: This study evaluated the effect of oxytocin administration prior to microwave ablation (MWA) of hypervascular uterine fibroids. Methods: Thirty-two patients with 38 hypervascular uterine fibroids (Adler blood flow grade 3) were equally apportioned to receive intravenous oxytocin infusion (0.32 U/min) 20 min before ultrasound-guided percutaneous MWA, or no oxytocin (control). Changes in Adler blood supply grade and myoma volume were observed via color Doppler ultrasonography (CDU). All patients underwent quantitative ablation with single or double needle and microwave power 50 W (180 s). Treatment continued for those who did not reach the therapeutic goal. The myoma necrotic volume was evaluated by contrast-enhanced ultrasound. Ablation rate was the percent of MRI nonenhanced myoma volume after treatment, relative to myoma volume before treatment, 2 days after surgery. Results: Twenty minutes after oxytocin administration, CDU showed significant decrease of blood vessels in myomas, and Adler blood supply decreased from grade 3 to grade 1 or grade 0 in 10 and 9 myomas, respectively. Myoma volumes were reduced by 2.12 ± 0.24%. Necrotic volumes in the oxytocin (control) groups were 36.96 ± 2.78 cm³ (22.68 ± 3.38 cm³) and ablation rates were 95.4 ± 2.7% (85.7 ± 3.3%; t = 12.68, 8.866, p = 0.001, both). No serious complication was noted. Conclusion: Intravenous oxytocin administered before percutaneous MWA of hypervascular uterine fibroids can effectively block the blood supply vessels of the myoma, reduce the heat sink effect, and thereby increase the ablation volume and improve the local therapeutic effect.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with hypervascular uterine fibroids, necrotic volume after microwave ablation was larger with oxytocin than in controls.
In plain wordsIn women with uterine fibroids, oxytocin before microwave ablation gave a larger area of destroyed fibroid tissue than no oxytocin.
Peptide
Oxytocin
Outcome
IncreaseNecrotic volume after microwave ablation
Study
n = 32
Comparator
No oxytocin (control)
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Studied dose
0.32 U/min · intravenousAs given in this study (human).
Measurements
Necrotic volume
36.96 cm3
oxytocin
Necrotic volume
22.68 cm3
control
Source sentences
Summary
Necrotic volumes in the oxytocin (control) groups were 36.96 ± 2.78 cm³ (22.68 ± 3.38 cm³) and ablation rates were 95.4 ± 2.7% (85.7 ± 3.3%; t = 12.68, 8.866, p = 0.001, both).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two patients with 38 hypervascular uterine fibroids (Adler blood flow grade 3) were equally apportioned to receive intravenous oxytocin infusion (0.32 U/min) 20 min before ultrasound-guided percutaneous MWA, or no oxytocin (control).
Show in the study text Report a problemFND-3143108004
02HumanNon-randomized trialEfficacy outcome
In patients with hypervascular uterine fibroids, the ablation rate was higher with oxytocin than in controls.
In plain wordsIn women with uterine fibroids, oxytocin before microwave ablation gave a higher ablation rate than no oxytocin.
Peptide
Oxytocin
Outcome
IncreaseAblation rate
Study
n = 32
Comparator
No oxytocin (control)
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Studied dose
0.32 U/min · intravenousAs given in this study (human).
Measurements
Ablation rate
95.4%
oxytocin
Ablation rate
85.7%
control
Source sentences
Summary
Necrotic volumes in the oxytocin (control) groups were 36.96 ± 2.78 cm³ (22.68 ± 3.38 cm³) and ablation rates were 95.4 ± 2.7% (85.7 ± 3.3%; t = 12.68, 8.866, p = 0.001, both).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two patients with 38 hypervascular uterine fibroids (Adler blood flow grade 3) were equally apportioned to receive intravenous oxytocin infusion (0.32 U/min) 20 min before ultrasound-guided percutaneous MWA, or no oxytocin (control).
Show in the study text Report a problemFND-3143108005
03HumanNon-randomized trialEfficacy outcome
In patients with hypervascular uterine fibroids, intravenous oxytocin significantly decreased blood vessels in myomas 20 minutes after administration.
In plain wordsIn women with uterine fibroids, intravenous oxytocin reduced blood vessels in the fibroids within 20 minutes.
Peptide
Oxytocin
Outcome
DecreaseBlood vessels in myomas on color Doppler ultrasonography
Study
n: not reported in source
Comparator
Baseline
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Studied dose
0.32 U/min · intravenousAs given in this study (human).
Source sentences
Summary
Twenty minutes after oxytocin administration, CDU showed significant decrease of blood vessels in myomas, and Adler blood supply decreased from grade 3 to grade 1 or grade 0 in 10 and 9 myomas, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two patients with 38 hypervascular uterine fibroids (Adler blood flow grade 3) were equally apportioned to receive intravenous oxytocin infusion (0.32 U/min) 20 min before ultrasound-guided percutaneous MWA, or no oxytocin (control).
Show in the study text Report a problemFND-3143108001
04HumanNon-randomized trialEfficacy outcome
In patients with hypervascular uterine fibroids, Adler blood supply decreased from grade 3 to grade 1 or grade 0 in 10 and 9 myomas, respectively, after oxytocin.
In plain wordsIn women with uterine fibroids, the blood supply grade of the fibroids fell after intravenous oxytocin.
Peptide
Oxytocin
Outcome
DecreaseAdler blood supply grade of myomas
Study
n: not reported in source
Comparator
Baseline
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Studied dose
0.32 U/min · intravenousAs given in this study (human).
Measurements
Myomas reaching Adler grade 1
10 myomas
after oxytocin
Myomas reaching Adler grade 0
9 myomas
after oxytocin
Source sentences
Summary
Twenty minutes after oxytocin administration, CDU showed significant decrease of blood vessels in myomas, and Adler blood supply decreased from grade 3 to grade 1 or grade 0 in 10 and 9 myomas, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two patients with 38 hypervascular uterine fibroids (Adler blood flow grade 3) were equally apportioned to receive intravenous oxytocin infusion (0.32 U/min) 20 min before ultrasound-guided percutaneous MWA, or no oxytocin (control).
Show in the study text Report a problemFND-3143108002
05HumanNon-randomized trialEfficacy outcome
In patients with hypervascular uterine fibroids, myoma volumes were reduced by 2.12 ± 0.24% after oxytocin.
In plain wordsIn women with uterine fibroids, fibroid volume fell slightly after intravenous oxytocin.
Peptide
Oxytocin
Outcome
DecreaseMyoma volume reduction
Study
n: not reported in source
Comparator
Baseline
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Studied dose
0.32 U/min · intravenousAs given in this study (human).
Measurements
Myoma volume reduction
2.12%
after oxytocin
Source sentences
Summary
Myoma volumes were reduced by 2.12 ± 0.24%.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two patients with 38 hypervascular uterine fibroids (Adler blood flow grade 3) were equally apportioned to receive intravenous oxytocin infusion (0.32 U/min) 20 min before ultrasound-guided percutaneous MWA, or no oxytocin (control).
Show in the study text Report a problemFND-3143108003
06HumanNon-randomized trialSafety outcome
In patients with hypervascular uterine fibroids, no serious complication was noted with oxytocin before microwave ablation.
In plain wordsIn women with uterine fibroids, no serious complication was noted with oxytocin before microwave ablation.
Peptide
Oxytocin
Outcome
No significant changeSerious complications
Study
n: not reported in source
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.32 U/min · intravenousAs given in this study (human).
Source sentences
Summary
No serious complication was noted.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-two patients with 38 hypervascular uterine fibroids (Adler blood flow grade 3) were equally apportioned to receive intravenous oxytocin infusion (0.32 U/min) 20 min before ultrasound-guided percutaneous MWA, or no oxytocin (control).
Show in the study text Report a problemFND-3143108006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 01:30 UTC
Study results updated
Version 1
9 Oct 2026, 02:48 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.